Table 4 Demographic and clinical parameters of patients with post-treatment haemolysis
Patient | Gender | Travel type | Country of infection | Anti-malarial treatment | Baseline parasitaemia | Other complications | Pre-existing medical conditions | Coombs test | Transfusions for post-treatment haemolysis |
|---|---|---|---|---|---|---|---|---|---|
1 | f | Tourism | Burkina Faso | Quinine (iv) + Clindamycin (po) + Artesunate (ir) | 30% | Acute renal failure (Peak creatinine: 8.5 mg/dl), QTc prolongation (550 ms) | Hypertension | DCT negative | Day 15 and Day 21 (2 units of packed red blood cells each) |
2 | m | VFR | Burkina Faso | Quinine (iv) + Doxycycline (po) + Artesunate (ir) | 25% | Acute renal failure (Peak creatinine: 2.2 mg/dl) | Newly diagnosed HIV-1 infection | DCT positive, warm auto-antibodies (IgG) | Day 14 (2 units of packed red blood cells) |
3* | f | Tourism | Uganda | Artesunate (iv) + Mefloquine (po) | 14% | - | - | DCT not done | None |
4* | m | Tourism | Gambia | Artesunate (iv) + Atovaquone/ Proguanil (po) | 21% | Acute renal failure (peak creatinine: 6.5 mg/dl) | Hypertension | DCT positive, Low titre of anti-E IgG antibodies | Day 14 and Day 21, 2 units of packed red blood cells |
5* | m | Tourism | Gambia/ Senegal | Artesunate (iv) + Atovaquone/ Proguanil (po) | 20% | Acute renal failure (peak creatinine: 7.0 mg/dl) | - | DCT negative | None |